Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials

被引：2
|
作者：
Ali, Faraat [1 ]
Sharma, Kamna [2 ]
Ali, Asad [3 ]
机构：
[1] Botswana Med Regulatory Authority, Lab Serv, Plot 112,Int Finance Pk, Gaborone, Botswana
[2] Indo Soviet Friendship Coll Pharm, Dept Pharmaceut Anal, Moga, Punjab, India
[3] Jamia Hamdard, Sch Chem & Life Sci, Dept Chem, New Delhi, India
来源：
CURRENT DRUG TARGETS | 2022年 / 23卷 / 09期
关键词：
Pegfilgrastim-apgf (Nyvepria); biosimilar; febrile neutropenia; non-myeloid cancer; FDA; anticancer drugs; ONCOLOGY; SAFETY; CT-P6;
D O I：
10.2174/1389450123666220408101152
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Pegfilgrastim-apgf (nyvepria) was currently approved by FDA for the treatment of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive anticancer drugs. It was developed by Pfizer, USA. It is a PEGylated leukocyte growth-stimulating factor indicated to reduce the incidence of febrile neutropenia in patients receiving anticancer drugs. Nyvepria is biosimilar to pegfilgrastim, approved by FDA on June 10, 2020. It is the fourth FDA-approved drug for the treatment of infection exhibiting febrile neutropenia. This review abridges the indicators in the development of nyvepria foremost to approval for the treatment of febrile neutropenia (FN), a biosimilar regulatory framework, and current updates on the clinical trials (CTs).
引用
收藏
页码：924 / 932
页数：9
相关论文
共 50 条
  • [31] Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
    Weycker, Derek
    Li, Xiaoyan
    Tzivelekis, Spiros
    Atwood, Mark
    Garcia, Jacob
    Li, Yanli
    Reiner, Maureen
    Lyman, Gary H.
    SUPPORTIVE CARE IN CANCER, 2017, 25 (02) : 439 - 447
  • [32] Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
    Lalami, Yassine
    Klastersky, Jean
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 120 : 163 - 179
  • [33] Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study
    Sun, Diana
    Andayani, Tri Murti
    Altyar, Ahmed
    MacDonald, Karen
    Abraham, Ivo
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 842 - 857
  • [34] Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
    Kamioner, Didier
    Fruehauf, Stefan
    Maloisel, Frederic
    Cals, Laurent
    Lepretre, Stephane
    Berthou, Christian
    BMC CANCER, 2013, 13
  • [35] Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study
    Tomomatsu, Takuya
    Shimizu, Hisanori
    Yokokawa, Takashi
    Fukada, Ippei
    Kawakami, Kazuyoshi
    Kobayashi, Kazuo
    Aoyama, Takeshi
    Suzuki, Wataru
    Sugisaki, Takahito
    Hashimoto, Koki
    Asano, Maimi
    Mori, Yuka
    Hara, Fumikata
    Takano, Toshimi
    Ohno, Shinji
    Yamaguchi, Masakazu
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2024, 144 (09): : 897 - 904
  • [36] Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
    Derek Weycker
    Xiaoyan Li
    Spiros Tzivelekis
    Mark Atwood
    Jacob Garcia
    Yanli Li
    Maureen Reiner
    Gary H. Lyman
    Supportive Care in Cancer, 2017, 25 : 439 - 447
  • [37] Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children
    Raisch, DW
    Holdsworth, MT
    Winter, SS
    Hutter, JJ
    Graham, ML
    VALUE IN HEALTH, 2003, 6 (02) : 158 - 166
  • [38] Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)
    Aapro, Matti
    Bokemeyer, Carsten
    Ludwig, Heinz
    Gascon, Pere
    Boccadoro, Mario
    Denhaerynck, Kris
    Gorray, Michael
    Krendyukov, Andriy
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (02) : 86 - 95
  • [39] Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice
    Weycker, Derek
    Danel, Aurelie
    Marciniak, Anne
    Bendall, Kate
    Lipsitz, Michael
    Pettengell, Ruth
    BMC CANCER, 2012, 12
  • [40] Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice
    Derek Weycker
    Aurelie Danel
    Anne Marciniak
    Kate Bendall
    Michael Lipsitz
    Ruth Pettengell
    BMC Cancer, 12
12345